NMPA Reduces Drug Review Timelines to 120 Days — What This Means for Biotech in China

In a landmark policy shift effective January 2025, China’s 国家药品监督管理局 (National Medical Products Administration, NMPA, Guójiā Yàopǐn Jiāndū Guǎnlǐ Jú) has compressed its standard drug review timeline from an average of 365 days to 120 calendar days — a 67% reduction that positions China among the fastest major drug regulators globally. This change, codified in the revised Drug Registration Regulation (药品注册管理办法, Yàopǐn Zhùcè Guǎnlǐ Bànfǎ), applies to both domestic and foreign-filed new drug applications (NDAs) and aims to accelerate patient access while aligning with International Council for Harmonisation (ICH) guidelines.

1. The Timeline Reduction: What Changed

The NMPA’s previous review cycle, which stretched 10–14 months for standard applications, has historically been a bottleneck for biotech companies seeking China market entry. The new 120-day window applies to the NMPA’s Center for Drug Evaluation (CDE, 药品审评中心, Yàopǐn Shěnpíng Zhōngxīn) technical review phase — the most time-consuming step — and excludes administrative processing and inspection periods, which typically add 30–60 days.

Key structural changes behind the acceleration include:

• Parallel review of chemistry, manufacturing, and controls (CMC) data alongside clinical trial results, rather than sequentially.
• Pre-submission communication — mandatory 60-day pre-NDA meeting to flag deficiencies before formal filing.
• Priority review expansion — drugs for rare diseases, pediatric indications, and innovative biologics now qualify for an even faster 90-day track.

The 120-day cap applies to both chemical drugs (化药, huàyào) and biologic products (生物制品, shēngwù zhìpǐn), though vaccines and blood products remain subject to additional 45-day inspection windows due to heightened safety oversight.

2. Impact on Biotech Companies: Speed vs. Scrutiny

For foreign biotech firms planning China launches, the faster timeline reduces capital burn and accelerates revenue generation. A drug that previously required $500,000–$1 million in bridging study costs and 18 months of regulatory waiting can now expect NMPA action within 4–6 months post-filing. However, the compressed timeline demands earlier and more rigorous preparation.

Since 2023, the NMPA has rejected or requested major amendments for 23% of NDAs within the first 60 days — a proportion expected to rise as reviewers enforce tighter submission quality standards. The CDE now issues a “refuse-to-file” letter if dossiers lack complete Module 3 (quality) or Module 5 (clinical study reports) data, with no possibility of resubmission under the 120-day clock.

For comparison, the U.S. FDA’s standard review is 10 months (300 days) and priority review 6 months (180 days), while the European Medicines Agency (EMA) averages 210 days for centralized procedures. China’s 120-day standard now outpaces both — but only for submissions that pass pre-screening.

The table underscores a critical trade-off: while China’s review window is shortest, its first-cycle rejection rate is also highest — 23% vs. FDA at 12%. This means companies that rush incomplete dossiers face costly rework and delays that can exceed the original timeline savings.

3. Comparison with Global Standards: China’s New Edge

The NMPA’s move aligns with China’s broader “14th Five-Year Plan for Biotech” (十四五生物医药规划, Shísì Wǔ Shēngwù Yīyào Guīhuà), which targets 30% reduction in average time-to-market for innovative drugs by 2026. The 120-day standard is already below the U.S. and EU benchmarks, but execution hinges on CDE staffing — the center added 450 reviewers in 2024, bringing its total to 1,200, yet each reviewer still manages 8–12 active dossiers versus the FDA’s average of 5–7.

For biotech companies comparing launch strategies, the decision framework is clear:

If your drug targets a disease with high prevalence in China (e.g., liver cancer, gastric cancer), and you have completed a local Phase I/II bridging trial, choose China-first filing — the 120-day review can put you on the market 6 months ahead of U.S. approval.
If your drug requires complex manufacturing data or has unresolved EMA/FDA questions, choose a staggered approach — use the NMPA’s new pre-NDA meeting to resolve issues in China before committing to full filing, to avoid the high rejection risk.

Key Takeaways for Foreign Biotech Executives

To leverage the 120-day timeline, biotech firms must adapt their China submission strategy. Here are three immediate actions:

1. Invest in local regulatory affairs talent — CDE reviewers expect face-to-face pre-NDA meetings conducted in Mandarin, with detailed familiarity of Chinese pharmacopoeia standards. A bilingual regulatory lead (费用, fèiyòng, annual cost ~$80,000–$120,000) is no longer optional.
2. Prepare Module 3 and Module 5 as gate documents — The CDE will issue a refuse-to-file if either module is incomplete. Allocate at least 8 weeks for internal quality checks before pre-NDA submission.
3. Budget for parallel manufacturing inspection — While the technical review is 120 days, on-site GMP inspection of foreign manufacturing sites (境外工厂检查, jìngwài gōngchǎng jiǎnchá) adds 45 days and requires a dedicated China-based liaison.

Three Pitfalls to Avoid

NEXT STEPS

To capitalize on the 120-day NMPA review window, begin with these three actions:

1. Review your pipeline against NMPA eligibility criteria. Read our Drug Registration Guide for Foreign Biotech for a step-by-step filing checklist.
2. Audit your clinical data package for Module 3 and Module 5 completeness. Our Pre-Submission Audit Service helps identify gaps before the pre-NDA meeting.
3. Assess your local team — do you have a bilingual regulatory affairs lead in place? See our guide on Hiring Regulatory Affairs Talent in China for hiring and retention strategies.

— China Gateway 360 —
Remote China market entry support, built around execution.